35
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department of Pathology and Laboratory Medicine Emory University School of Medicine

Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Embed Size (px)

Citation preview

Page 1: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

Michael R. Rossi, PhD, FACMG

Assistant Professor

Division of Cancer Biology, Department of Radiation Oncology

Department of Pathology and Laboratory Medicine

Emory University School of Medicine

Page 2: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Disclosures

Not a paid consultant to Agilent, nor a share holder

2

Page 3: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Outline 1. Introduction to Cancer Genomics

2. NGS Oncology Assay Basics

a. Instrument Footprint

b. Nucleic Acid: DNA, RNA, Both?

c. Library Prep: Hybrid Capture vs Amplicon

d. Sequencing: Depth of Coverage and Data Quality

e. Bioinformatics: Compute, Storage, Workflow

f. Data Interpretation: “Knowledge is power”

g. Reporting

3. Questions

3

Page 4: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Cancer Genomics

4

Page 5: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

5

Page 6: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Cirello et al., Nature Genetics 45, 1113–1120 (2013)

TCGA PanCancer Data

6

Page 7: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Cirello et al, Emerging landscape of oncogenic signatures across human cancers Nature Genetics 45, 1127–1133 (2013),

7

Page 8: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Genomic Medicine 101

8

Page 9: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Copyright © 2014 American Medical Association. All rights reserved.

From: Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

JAMA. 2014;311(19):1998-2006. doi:10.1001/jama.2014.3741

Survival Comparisons ALK indicates anaplastic lymphoma kinase gene; EGFR(s), epidermal growth factor receptor gene (sensitizing); EGFR(o), epidermal growth factor

receptor gene (other); KRAS, Kirsten rat sarcoma; NA, not applicable.A, Median survival (95% CI): oncogenic driver + no targeted therapy, 2.38 (1.81-2.93); oncogenic

driver + targeted therapy, 3.49 (3.02-4.33); no oncogenic driver, 2.08 (1.84-2.46). B, Survival by oncogenic driver detected for patients with the 5 most frequent oncogenic

drivers and targeted treatment. Median survival (95% CI): EGFR(s), 3.78 (2.77-NA); EGFR(o), 2.70 (1.42-NA); ALK, NA (2.80-NA); KRAS, 4.85 (1.30-NA); doubletons

(oncogenic drivers in 2 genes), 2.69 (1.94-NA). Vertical tick marks are censoring events.

Figure Legend:

Lung Cancer Mutation Consortium v1

Page 10: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Shaw AT et al. N Engl J Med 2016;374:54-61.

Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Page 11: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Figure 1: Somatic mutation frequencies observed in exomes from 3,083 tumour–normal pairs

Lawrence et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Nature 499, 214–218 (11 July 2013)

11

Page 12: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

12

Page 13: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

13

Initial

Diagnosis

• Comprehensive Testing (Discovery)

• Hybrid Capture RNA-Seq (Differential Gene Expression, Coding Fusions/Mutations)

• Hybrid Capture DNA-Seq (Copy Number, Mutations, Fusions)

Minimal

Residual

Disease

• Targeted Testing (Response to Treatment)

• Ultra Deep DNA Sequencing

• Neoantigen

• ctDNA/exome (Digital PCR, Lower complexity Hybrid Capture or Amplicon NGS Panels)

Disease

Progression

• Comprehensive Testing (Discovery)

• RNA-Seq (Differential Gene Expression, Coding Fusions/Mutations)

• Hybrid Capture DNA-Seq (Copy Number, Mutations, Fusions)

Oncology Testing Paradigm

Page 14: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

14

Data Management

Page 15: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

NGS Oncology Assay Basics Instrument Footprint Nucleic Acid: DNA, RNA, Both? Library Prep: Hybrid Capture vs Amplicon Sequencing: Depth of Coverage and Data Quality Bioinformatics: Compute, Storage, Workflow Data Interpretation: “Knowledge is power” Reporting

15

Page 16: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Laboratory Management System (LIMS)

Nucleic Acid QC

Library Prep Automation / Liquid Handling

Sequencer

Compute and Storage (Cloud vs Local)

16

DIN/RIN

Measurement

Pico Green

Fluorometer Quantitative

PCR Spectrophotometer

Page 17: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

NGS Oncology Assay Basics Instrument Footprint Nucleic Acid: DNA, RNA, Both? Library Prep: Hybrid Capture vs Amplicon Sequencing: Depth of Coverage and Data Quality Bioinformatics: Compute, Storage, Workflow Data Interpretation: “Knowledge is power” Reporting

17

Page 18: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

18

Page 19: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

NGS Oncology Assay Basics Instrument Footprint Nucleic Acid: DNA, RNA, Both? Library Prep: Hybrid Capture vs Amplicon Sequencing: Depth of Coverage and Data Quality Bioinformatics: Compute, Storage, Workflow Data Interpretation: “Knowledge is power” Reporting

19

Page 20: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

DNA and RNA Libraries

Hybrid Capture

Whole Transcriptome

Fusions

Amplicon (PCR)

20

Page 21: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

NGS Oncology Assay Basics Instrument Footprint Nucleic Acid: DNA, RNA, Both? Library Prep: Hybrid Capture vs Amplicon Sequencing: Depth of Coverage and Data Quality Bioinformatics: Compute, Storage, Workflow Data Interpretation: “Knowledge is power” Reporting

21

Page 22: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

22

Uniform Coverage

0-213

0-221

0-208

0-208

Page 23: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

23

Mutation Detection

KRAS c.436G>A [p.A146T] _ENST00000256078

Total count: 212

A : 0

C : 66 (31%, 40+, 26- )

G : 0

T : 146 (69%, 95+, 51- )

N : 0

Page 24: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

NGS Oncology Assay Basics Instrument Footprint Nucleic Acid: DNA, RNA, Both? Library Prep: Hybrid Capture vs Amplicon Sequencing: Depth of Coverage and Data Quality Bioinformatics: Compute, Storage, Workflow Data Interpretation: “Knowledge is power” Reporting

24

Page 25: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

25

Bioinformatics Conundrum?

Expensive

Complicated

Page 26: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

26

FASTQ – Data QC – Align (.BAM/.BAI) – Call Variants (.VCF) – Annotate (.MAF/.TSV)

https://www.coursera.org/learn/galaxy-project

Page 27: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Galaxy Workflows http://goeckslab.org/

Jeremy Goecks GEORGE WASHINGTON UNIVERSITY

27

Page 28: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

NGS Oncology Assay Basics Instrument Footprint Nucleic Acid: DNA, RNA, Both? Library Prep: Hybrid Capture vs Amplicon Sequencing: Depth of Coverage and Data Quality Bioinformatics: Compute, Storage, Workflow Data Interpretation: “Knowledge is power” Reporting

28

Page 29: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

GIGO- Garbage In, Garbage Out

The integrity of the output is

dependent on the integrity of the

input.

George Fuechsel

Page 30: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

30

C>T or G>A

Lawrence et al., Nature 499, 214–218 (11 July 2013)

Page 31: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Is a normal control required to call

somatic or germline mutations?

No Yes 31

Page 32: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

NGS Oncology Assay Basics Instrument Footprint Nucleic Acid: DNA, RNA, Both? Library Prep: Hybrid Capture vs Amplicon Sequencing: Depth of Coverage and Data Quality Bioinformatics: Compute, Storage, Workflow Data Interpretation: “Knowledge is power” Reporting

32

Page 33: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Lung Cancer Biomarkers Guidelines

33

Page 34: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

34

Page 35: Disclosures - Agilent · Shaw AT et al. N Engl J Med 2016;374:54-61. Acquired Resistance to Lorlatinib and Resensitization to Crizotinib in NSCLC

Questions?

35

PR7000-0257